Team:KAIST-Korea/Notebook/Memo/Etc

From 2010.igem.org

(Difference between revisions)
(Info & Idea)
Line 15: Line 15:
<html><a href="https://2010.igem.org/Team:KAIST-Korea/Notebook/Memo/Etc"><img src="https://static.igem.org/mediawiki/2010/thumb/3/39/Etc.jpg/230px-Etc.jpg"></a></html>
<html><a href="https://2010.igem.org/Team:KAIST-Korea/Notebook/Memo/Etc"><img src="https://static.igem.org/mediawiki/2010/thumb/3/39/Etc.jpg/230px-Etc.jpg"></a></html>
</td></tr></table>
</td></tr></table>
-
== <span style=font-size:20px> <b> Info & Idea </b> </span> ==
+
== <span style=font-size:20px> <b> Info & Idea </b> </span><b>We hadle information and idea at ETC </b> ==
-
<b>We hadle information and idea at ETC </b>
+
<br>
<br>
<span style=font-size:15px> <b> MAB </b> </span>
<span style=font-size:15px> <b> MAB </b> </span>

Revision as of 12:04, 15 July 2010

 

Info & Idea We hadle information and idea at ETC


MAB
Until now, mab is composed of mouse's antigen injection, splenocyte seperation, fusion between splenocyte and myeloma cell, and antibody making cell selection.
Myeloma cell, which is myelogenous leukemia, doesn't have antibody produce ability, because it is immobilized, when it fuses B-cell in splenocyte, it can take a culture and make strain to produce antibody.
But, because of cancer cell's unique lability, if it take a long period culture, it can be cloning again.
Most of all, fusion of after fusion selection spends lots of cost and time.
Because B-cell activation needs T-cell, it is hard to take mouse's antigen injection process in vitro.
So to save time, elemination of fusion is needed.
To use transfomation protocol, if cell growth division gene insert it, it is possible.